Araştırma Makalesi

Evaluation of esophageal motor functions in patients diagnosed with primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis

Cilt: 47 Sayı: 1 31 Mart 2022
PDF İndir
EN TR

Evaluation of esophageal motor functions in patients diagnosed with primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis

Abstract

Purpose: The aim of this study was to evaluate the relationship between autoimmune liver diseases and esophageal motor disorders (EMD). Materials and Methods: 63 patients diagnosed with primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) and followed up in our hospital were included in the study. The control group consisted of 33 patients. Upper gastrointestinal endoscopy, esophageal motility study and pH meter tests were performed on all participants. Results: Of the 63 patients included in the study 49.2% of the patients, EMD was detected while 31.7% of them had pathology in the pH meter. The rates of EMD of patients with PBC, PSC and AIH were 50%, 63.6%, and 42.9%, respectively while the pathology rates of the pH meter were found as 25%, 54.5%, and 28.6%, respectively. Statistically significant difference was found between autoimmune liver disease and control group in terms of esophageal motor diseases. As a result of manometric examination, median lower esophageal sphincter resting pressure was significantly lower in autoimmune liver patients compared to the control group. Conclusion: Our study presents that EMD is common in patients with PBC, PSC, and AIH, and that the presence of cirrhosis has no impact on the development of EMD.

Keywords

primary biliary cholangitis , primary sclerosing cholangitis , autoimmune hepatitis , esophageal motility disorder

Kaynakça

  1. Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis. 2013;4:119-41.
  2. Brahim I, Brahim I, Hazime R, Admou B. Autoimmune hepatitis: immunological diagnosis. Presse Med. 2017;46:1008-19.
  3. Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114:48-63.
  4. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet. 2018;391:2547-59.
  5. Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018;9:609.
  6. Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res. 2019;2019:9437043.
  7. Selmi C, Generali E, Gershwin ME. Rheumatic manifestations in autoimmune liver disease. Rheum Dis Clin North Am. 2018;44:65-87.
  8. John E. Pandolfino, Peter J. Kahrilas, Hogenauer C. Esophageal neuromuscular function and motility disorders. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed, Feldman M, Friedman LS, Brandt LJ (Eds), Philadelphia. 2020;1692
  9. Kahrilos PJ, Pandolfino JE. Motility of the esophagus. In: Yamada T, editor. Textbook of Gastroenterology UK: Blackwell publishing. 2009;740-771 B.
  10. Volter F, FainO, Mathieu E, Thomas M. Esophageal function and Sjögren's syndrome. Dig Dis Sci. 2004;49:248–53.

Kaynak Göster

MLA
Gökbulut, Volkan, vd. “Evaluation of esophageal motor functions in patients diagnosed with primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis”. Cukurova Medical Journal, c. 47, sy 1, Mart 2022, ss. 21-28, doi:10.17826/cumj.984551.